Modern aspects of prophylaxls and therapy for venous thrombo-embolic disease

Australian and New Zealand Journal of Surgery

Volumn 68, Issue 7, 1998, Pages 463-468

  Bergqvist, David ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dextran; Fatal pulmonary embolism; Hirudan; Low molecular weight heparins; Venous thrombo embolism

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARDEPARIN; CERTOPARIN; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; DEXTRAN; ENOXAPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; CHONDROITIN SULFATE; FIBRINOLYTIC AGENT; HEPARAN SULFATE;

BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRACTICE GUIDELINE; SPINAL CORD HEMORRHAGE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; DRUG ADMINISTRATION; DRUG COMBINATION; REVIEW; THROMBOPHLEBITIS;

CHONDROITIN SULFATES; DERMATAN SULFATE; DEXTRANS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HUMANS; PULMONARY EMBOLISM; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0031595113     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. Bergqvist D, Jendteg S, Johansen L, Persson K, Ödegaard K. The cost of long-term complications of deep venous thrombosis of the lower extremity: An analysis of a defined patient population from Sweden. Ann. Intern. Med. 1997; 126: 454-7.
2. McLean J. The thromboplastic action of cephalin. Am. J. Physiol. 1916; 41: 250-70.
3. Howell WH, Holt E. Two near factors in blood coagulation. Am. J. Physiol. 1918; 47: 328-41.
4. Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976; 66: 90-3.
5. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sonderström G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb. Res. 1976; 9: 575.
6. Lam LH, Silberg JA, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem. Biophys. Res. Commun. 1976; 69: 570-7.
7. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
8. Esquivel CO, Bergqvist D, Björck C-G, Nilsson B. Effect of heparin and a heparinoid on platelet activity and microvascular haemostasis in vivo. Eur. Surg. Res. 1982; 14: 154.
9. Collignon F, Frydman A, Caplain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins. Dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. 1995; 73: 630-40.
10. Cadroy Y, Pourrat J, Baladre MF. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb. Res. 1991; 63: 385-90.
11. Holst J, Lindblad B, Bergqvist D et al. Protamine neutralization of intravenous and subcutaneous LMWH (tinzaparin, Logiparin): An experimental investigation in healthy volunteers. Blood Coagul. Fibrinolysis 1995; 5: 795-803.
12. Bergqvist D. Review of clinical trials of low molecular weight heparins. Eur. J. Surg. 1992; 158: 67-78.
13. Jørgensen LN, Wille-Jørgensen P, Hauch, O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br. J. Surg. 1993; 80: 689-704.
14. Nurmohamed MT, Rosendaal FR, Büller HR et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992; 340: 152-6.
15. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20.
16. Kakkar VV. Efficacy and safety of clivarin® and other LMWHs in general surgery: A meta-analysis. Blood Coagul. Fibrinolysis 1993; 4: S23-7.
17. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann. Intern. Med. 1993; 119: 1105-12.
18. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-5.
19. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses. Br. J. Surg. 1997; 84: 750-9.
20. Mätzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir. Scand. 1990; 156: 445-50.
21. The Danish Enoxaparin Study Group. Low molecular weight heparin (enoxaparin) vs dextran-70: The prevention of postoperative deep vein thrombosis after total hip replacement. Arch. Intern. Med. 1991; 151: 1621-4.
22. Reiertsen D, Larsen S, Størkson R et al. Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery: A play-the-winner-designed study. Scand. J. Gastroenterol. 1993; 28: 1015-20.
23. Pezzuoli G, Serneri GGN, Settembrini P et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). Int. Surg. 1989; 74: 205-10.
24. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: Comparison of low-molecular-weight heparin and unfractionated heparin. J. Bone Joint Surg. Am. 1991; 73A: 484-93.
25. Collins R, Scrimgeour A, Yusuf S, Phil D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopaedic, and urologic surgery. N. Engl. J. Med. 1988; 318: 1162-73.
26. Planes A, Vochelle N, Mazas F et al. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb. Haemost. 1988; 60: 407-10.
27. Leyvraz PF, Bachmann F, Hoek J et al. Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543-8.
28. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. Arch. Orthop. Trauma Surg. 1992; 111: 110-20.
29. Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br. J. Surg. 1995; 82: 496-501.
30. International Consensus Statement. Prevention of Venous Thromboembolism. London: Med-Orion Publ. Comp. 1997.
31. Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br. J. Surg. 1996; 83: 1548-52.
32. Bergqvist D, Mätzsch T, Burmark US et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in the prevention of thrombosis after elective general abdominal surgery. Br. J. Surg. 1988; 75: 888-91.
33. Mätzsch T, Bergqvist D, Burmark US, Holmer E, Söderberg K. The influence of surgical trauma on factor XaI-and IIaI-activity and heparin concentration after a single dose of low molecular weight heparin. Blood Coagul. Fibrinolysis 1991; 2: 651-7.
34. Turpie A, Levine M, Hirsch J. A randomized controlled trial of low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N. Engl. J. Med. 1986; 315: 925-29.
35. Spiro TE, Johnson GJ, Christie MJ et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann. Intern. Med. 1994; 121: 81-9.
36. Colwell CW, Spiro TE, Trowbridge AA et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J. Bone Joint Surg. Am. 1994; 76A: 3-14.
37. Hull RD, Raskob G, Pineo G et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med 1993; 329 1370-6.
38. Hull R, Pineo GF, Valentine KA, Stagg V, Brant RF. Preoperative enoxaparin is more effective than postoperative enoxaparin in the prevention of deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR): A pooled analysis. Thromb. Haemost. 1997; 78: (Suppl.) 387.
39. Bergqvist D, Lindblad B, Mätzsch T. Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia: Is there a risk? Acta Anaesthesiol. Scand. 1992; 36: 605-9.
40. Wolf H. Experience with regional anaesthesia in patients receiving low molecular weight heparins. Semin. Thromb. Hemost. 1993; 19: S152-9.
41. Vandermeulen AP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth. Analg. 1994; 79: 1165-77.
42. Scurr J, Coleridge-Smith P, Hasty JH. Deep venous thrombosis: A continuing problem. BMJ 1988; 297: 28.
43. Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patients. Br. J. Surg. 1985; 72: 105-8.
44. Huber O, Bounemaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: An underestimated risk. Arch. Surg. 1992; 127: 310-13.
45. Bergqvist D, Benoni G, Björgell O et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N. Engl. J. Med. 1996; 335: 696-700.
46. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-vein thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
47. Bergqvist D. Dextran. In: Goldhaber S (ed.). Prevention of Venous Thromboembolism. New York: Marcel Dekker Inc., 1993; 167-215.
48. Ljungström K-G. Dextran prophylaxis of fatal pulmonary embolism. World J. Surg. 1983; 7: 767-72.
49. Ljungström K-G, Renck H, Hedin H, Richter W, Wilhelm B. Hapten inhibitor and dextran prophylaxis. Anaesthesia 1988; 43: 729-32.
50. Ljungström K-G. Safety of dextran in relation to other colloids: Ten years experience with hapten inhibition. Infusionsther. Transfusionsmed. 1993; 20: 206-10.
51. Matthiasson SE, Lindblad B, Mätzsch T, Holst J, Bergqvist D. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb. Haemost. 1994; 71: 363-5.
52. Lisander B, Jacobsson S-A, Ivarsson I, Vegfors M, Engdahl O. Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty. Eur. J. Surg. 1996; 162: 861-6.
53. Dahl O, Walsøe H, Aspelin T, Røise O, Arnesen H, Lyberg T. Concomitant use of dextran-70 (Macrodex) and low molecular weight heparin (dalteparin) do not increase major orthopaedic surgery-related perioperative bleeding compared to dextran-70 alone. Thromb. Haemost. 1997; 78: (Suppl.) 290.
54. Gallus A, Cade J, Ockelford P et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb. Haemost. 1993; 70: 562-7.
55. Hoeck JA, Nurmohamed MT, Hamelynck KJ et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb. Haemost 1992; 67: 28-32.
56. Turpie A, Gent M, Côte R et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann. Intern. Med. 1992; 117: 353-7.
57. Bergqvist D, Kettunen K, Fredin H et al. Thromboprophylaxis in hip fracture patients: A prospective randomized comparative study between Org 10172 and dextran 70. Surgery 1991; 109: 617-622.
58. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture in the hip. J. Bone Joint Surg. Am. 1991; 73A: 494-502.
59. Eriksson BI, Wille-Jorgensen P, Kälebo P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. 1997; 337: 1329-35.
60. Eriksson B, Ekman S, Lindbratt S. et al. Prevention of thromboembolism with use of recombinant hirudin: Results of a double-blind multicenter trial comparing the efficacy of desirudin (Revasc™) with that of unfractionated heparin in patients having a total hip replacement. J. Bone Joint Surg. Am. 1997; 79A: 326-33.
61. Warwick D, Harrison J. Pneumatic plantar compression versus low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement. Thromb. Haemost. 1997; 78: (Suppl.) 489.
62. Murray DW, Britton AR, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J. Bone Joint Surg. Br. 1996; 78B: 863-70.
63. Nurmohamed MT, van Riel AM, Henkens CMA et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb. Hemost. 1996; 75: 233-8.
64. Agnelli G, Pivella F, Buonristiani P et al. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: A randomized double blind venography study. Thromb. Haemost. 1997; 78: (Suppl.) 386.
65. Hull DH, Raskob GE, Pineo GF. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 1992; 326: 975-82.
66. Lindmarker P, Holmström M, Granqvist S, Johnson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb. Haemost. 1994; 72: 186-90.
67. Leizorovicz A, Simonneau G, Decousus H, Boisse JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: A meta-analysis. BMJ 1994; 309: 229-304.
68. Tapson VD, Hull RD. Management of venous thromboembolic disease: The impact of low-molecular-weight heparin. Clin. Chest Med. 1995; 16: 281-94.
69. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch. Intern. Med. 1995; 155: 601-7.
70. Dalsgaard Nielsen J, Landorph A. Lavmolekylært heparin versus ufraktioneret heparin ved behandling af dyb venetrombose: En metaanalyse. Ugeskr. Laeger. 1994 156: 5844-9.
71. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am. J. Med. 1996; 100: 269-77.
72. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. Drugs 1996; 52 (suppl.): 30-7.
73. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N. Engl. J. Med. 1997; 337: 657-62.
74. Simoneau G, Sors H, Charbonnier B et al. for the THÉsÉE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. 1997; 337: 663-8.
75. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 1995; 334: 677-81.
76. Koopman MMW, Prandoni P, Piovella F et al. for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 1996; 334: 682-7.
77. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin*) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost. 1994; 71: 7-11.
78. Pini M, Aiello S, Manotti C et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb. Haemost. 1994; 72: 191-7.
79. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial. World J. Surg. 1996; 20: 521-7.
80. International Multicenter Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; ii: 45-51.
81. Gruber U, Saldeen T, Brokop T. Incidence of fatal postoperative pulmonary embolism with dextran 70 and low-dose heparin: An international multicenter study. BMJ 1980; 280: 69-72.
82. Gruber U. Prevention of fatal postoperative pulmonary embolism by heparin dihydroergotamine or dextran 70. Br. J. Surg. 1982; 69: S54-8.
83. Bergqvist D. Dextran. In: Verstraete M (ed.). Cardiovascular Thrombosis: Thrombocardiology. Philadelphia: Lippincott-Raven. 1998.
84. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy III: Reduction of venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-46.
85. Dahl O, Andreasen G, Aspelin T et al. Prolonged thromboprophylaxis following hip replacement surgery: Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb. Haemost. 1997; 77: 26-31.
86. Lassen MR, Borris LC for the Danish Prolonged Prophylaxis Study Group. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty: A placebo-controlled trial. Drugs 1996; 52 (Suppl.): 7: 47-54.